Skip to main content
SpringerLink
Log in

Pharmacologic Evaluation of Sulfasalazine, FTY720, and Anti-IL-12/23p40 in a TNBS-Induced Crohn’s Disease Model

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis has been used as an inflammatory bowel disease (IBD), Crohn’s disease (CD), preclinical model. However, published data on pharmacologic and therapeutic efficacy testing of this model are limited. FTY720 inhibits lymphoid cell trafficking in inflammatory conditions and is of interest to treat IBD.

Aim

We investigated the pharmacologic therapeutic efficacy of sulfasalazine, FTY720, and anti-IL-12/23p40, in a TNBS CD model.

Methods

Female, 7-week-old, BALB/c mice were given sulfasalazine orally (PO) and intraperitoneally (IP) at 10 mg/kg, FTY720 at 3 mg/kg PO, and mouse anti-IL-12/23p40 at 25 mg/kg IP. Vehicle groups given PO either phosphate-buffered saline/water or 40% ethanol served as controls. Pharmacologic efficacy was assessed using body weight loss, clinical scores of diarrhea and intestinal gross pathology, and colon weight parameters.

Results

Sulfasalazine and FTY720 treatment did not prevent body weight loss or reduce clinical scores of diarrhea or intestinal gross pathology, when compared with vehicle treatment. However, anti-IL-12/23p40 treatment showed significant efficacy by preventing body weight loss, reducing clinical scores of diarrhea, and reducing intestinal gross pathologic lesions, when compared with vehicle-treated animals. Sulfasalazine, anti-IL-12/23p40, and FTY720 were not effective in reducing colon weight.

Conclusion

With the exception of anti-IL-12/23p40, sulfasalazine, and FTY720 did not demonstrate full pharmacologic efficacy in our TNBS CD model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807–4812.

    PubMed  CAS  Google Scholar 

  2. Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology. 2002;123:554–565.

    Article  PubMed  CAS  Google Scholar 

  3. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–3182.

    Article  PubMed  Google Scholar 

  4. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance. J Immunol. 1996;157:2174–2185.

    PubMed  CAS  Google Scholar 

  5. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immuno. 2002;Chapter 15:Unit 15.19.

  6. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: Top-down versus step-up. Med Clin North Am. 2010;94:1–18 in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995–999.

    Article  Google Scholar 

  7. Takabe K, Paugh SW, Milstien S, et al. “Inside-out” signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev. 2008;60:181–195.

    Article  PubMed  CAS  Google Scholar 

  8. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767–1773.

    Article  PubMed  Google Scholar 

  9. Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn’s disease: Are they relevant for therapeutic options? Swiss Med Wkly. 2009;139:527–534.

    PubMed  CAS  Google Scholar 

  10. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995–999.

    Article  PubMed  Google Scholar 

  11. Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs. 1986;32:18–26.

    Article  PubMed  CAS  Google Scholar 

  12. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163–1174.

    Article  PubMed  CAS  Google Scholar 

  13. Daniel C, Sartory N, Zahn N, et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4 + CD25 + regulatory T cells. J Immunol. 2007;178:2458–2468.

    PubMed  CAS  Google Scholar 

  14. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281–1290.

    Article  PubMed  CAS  Google Scholar 

  15. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol. 1997;148:567–576.

    Article  PubMed  CAS  Google Scholar 

  16. Macfarlane GT, Blackett KL, Nakayama T, et al. The gut microbiota in inflammatory bowel disease. Curr Pharm Des. 2009;15:1528–1536.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was conducted at MD Biosciences and sponsored and supported by Pfizer Worldwide Research and Development.

Author information

Authors and Affiliations

  1. Drug Safety R&D, Pfizer Worldwide Research and Development, 35 CambridgePark Dr, Cambridge, MA, 02140, USA

    Zaher A. Radi, Deborah M. Heuvelman, Jaime L. Masferrer & Ericka L. Benson

Authors
  1. Zaher A. Radi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah M. Heuvelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime L. Masferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ericka L. Benson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zaher A. Radi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Radi, Z.A., Heuvelman, D.M., Masferrer, J.L. et al. Pharmacologic Evaluation of Sulfasalazine, FTY720, and Anti-IL-12/23p40 in a TNBS-Induced Crohn’s Disease Model. Dig Dis Sci 56, 2283–2291 (2011). https://doi.org/10.1007/s10620-011-1628-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1628-8

Keywords

Search

Navigation